MaxCyte, Inc. (MXCT)
Largest Insider Buys in Sector
MXCT Stock Price History Chart
MXCT Stock Performance
About MaxCyte, Inc.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. …
Insider Activity of MaxCyte, Inc.
Over the last 12 months, insiders at MaxCyte, Inc. have bought $489,066 and sold $1.14M worth of MaxCyte, Inc. stock.
On average, over the past 5 years, insiders at MaxCyte, Inc. have bought $16.03M and sold $15.32M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Masoud Maher (President and CEO) — $489,066.
The last purchase of 70,443 shares for transaction amount of $345,241 was made by Masoud Maher (President and CEO) on 2024‑06‑10.
List of Insider Buy and Sell Transactions, MaxCyte, Inc.
| 2024-12-09 | Sale | director | 2,495 0.0021% | $3.79 | $9,459 | +2.64% | ||
| 2024-12-06 | Sale | director | 505 0.0005% | $3.70 | $1,869 | +18.75% | ||
| 2024-11-01 | Sale | director | 47,689 0.0448% | $3.72 | $177,403 | -4.77% | ||
| 2024-10-28 | Sale | director | 3,000 0.0028% | $3.72 | $11,166 | 0.00% | ||
| 2024-10-02 | Sale | director | 21,607 0.0196% | $3.71 | $80,162 | -1.87% | ||
| 2024-10-01 | Sale | director | 26,082 0.0241% | $3.78 | $98,590 | -0.81% | ||
| 2024-09-26 | Sale | director | 3,000 0.0028% | $3.82 | $11,460 | 0.00% | ||
| 2024-09-04 | Sale | director | 29,767 0.0288% | $3.97 | $118,175 | -3.33% | ||
| 2024-09-03 | Sale | director | 17,922 0.0171% | $4.10 | $73,480 | -7.70% | ||
| 2024-08-26 | Sale | director | 3,000 0.0028% | $4.28 | $12,840 | -12.47% | ||
| 2024-08-02 | Sale | EVP, GLOBAL SALES | 17,857 0.017% | $4.36 | $77,874 | -11.21% | ||
| 2024-08-01 | Sale | EVP, GLOBAL SALES | 15,476 0.0147% | $4.54 | $70,261 | -15.10% | ||
| 2024-07-26 | Sale | director | 3,000 0.0028% | $4.75 | $14,238 | -19.00% | ||
| 2024-07-09 | Sale | EVP, GLOBAL SALES | 13,531 0.0131% | $4.03 | $54,584 | 0.00% | ||
| 2024-07-08 | Sale | EVP, GLOBAL SALES | 19,802 0.0192% | $4.03 | $79,782 | 0.00% | ||
| 2024-06-27 | Sale | director | 10,000 0.0096% | $3.99 | $39,900 | 0.00% | ||
| 2024-06-20 | Sale | EVP, GLOBAL SALES | 33,333 0.0279% | $4.09 | $136,465 | -4.81% | ||
| 2024-06-10 | President and CEO | 70,443 0.0666% | $4.90 | $345,241 | -18.75% | |||
| 2024-06-07 | President and CEO | 29,557 0.0283% | $4.87 | $143,824 | -17.08% | |||
| 2024-03-26 | Sale | director | 5,000 0.0049% | $4.41 | $22,025 | -5.85% |
Insider Historical Profitability
| Masoud Maher | President and CEO | 100000 0.0948% | $4.24 | 2 | 3 | |
| Casdin Partners Master Fund, L.P. | 10 percent owner | 10000000 9.4802% | $4.24 | 1 | 2 | <0.0001% |
| DOUGLAS RICHARD | director | 100000 0.0948% | $4.24 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $30.29M | 6.9 | 7.23M | -1.52% | -$468,496.47 | <0.01 | |
| Cadian Capital Management LP | $27.49M | 6.26 | 6.56M | +16.22% | +$3.84M | 0.98 | |
| Millennium Management LLC | $25.86M | 5.89 | 6.17M | +23.12% | +$4.86M | 0.02 | |
| The Vanguard Group | $22.4M | 5.1 | 5.35M | +1.23% | +$272,366.76 | <0.0001 | |
| Vitruvian Partners | $21.13M | 4.81 | 5.04M | 0% | +$0 | 6.7 |